Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease-Reference-Cited by-同舟云学术

Effect of Dapagliflozin on Alanine Aminotransferase Improvement in Type 2 Diabetes Mellitus with Non-alcoholic Fatty Liver Disease

Published:2018 Issue:3 Volume:33 Page:387
ISSN:2093-596X
Container-title:Endocrinology and Metabolism
language:en
Short-container-title:Endocrinol Metab

Author:

Choi Dug-Hyun¹^ORCID,Jung Chan-Hee¹^ORCID,Mok Ji-Oh¹^ORCID,Kim Chul-Hee¹^ORCID,Kang Sung-Koo¹^ORCID,Kim Bo-Yeon¹^ORCID

Affiliation:

1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.

Funder

Soonchunhyang University

Publisher

Korean Endocrine Society

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://synapse.koreamed.org/pdf/10.3803/EnM.2018.33.3.387

Reference34 articles.

1. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030

2. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes

3. The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter

4. Non-alcoholic fatty liver disease and diabetes

5. Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of baseline clinical characteristics among people with type 2 diabetes on second-line therapy previously added with dapagliflozin or another oral glucose-lowering drug: AGORA study;Clínica e Investigación en Arteriosclerosis;2024-06

2. Comparative effectiveness of sodium‐glucose co‐transporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real‐world data analysis;Diabetes, Obesity and Metabolism;2023-12-12

3. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review;European Journal of Clinical Pharmacology;2023-11-08

4. Swimming exercise ameliorates insulin resistance and nonalcoholic fatty liver by negatively regulating PPARγ transcriptional network in mice fed high fat diet;Molecular Medicine;2023-10-31

5. Prospects of using sodium-glucose co-transporter-2 (SGLT-2) inhibitors in patients with metabolic-associated fatty liver disease (MAFLD);Diabetes Obesity Metabolic Syndrome;2023-10-27